Pay in 4 interest-free payments of $5.75 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
NEWS Blockbuster obesity drug leads to better health in people with HIV Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time Subscribe to this journal Receive 52 print issues and online access $199.00 per year only $3.83 per issue Rent or buy this article Prices vary by article type from$1.95 to$39.95 Prices may be subject to local taxes which are calculated during checkout Nature 627 , 477-478 (2024) doi: References Gmez-Ayerbe, C
In addition, AT remains the most commonly studied source of immune-mediated inflammation in obesity
Se han reportado complicaciones de retinopata diabtica con semaglutida, probablemente relacionadas con la reduccin rpida de la glucemia en pacientes con retinopata preexistente, similar a lo observado con insulina
Results: The meta-analysis comprised 16 studies and 5,997 patients
US$ 21.21
US$ 23.58
US$ 27.53
US$ 21.35
